If you are passionate about Advancing Human Health with a focus on equitable access to high quality biosimilar therapies, we at Bio Usawa are looking forward to meeting you at CPHI Frankfurt 2025 in Germany, 28-30 October.

To learn more about the rapid approval of our flagship biosimilar product for eye disease, BioUcenta™ (ranibizumab), by the Rwanda FDA, please visit: https://lnkd.in/gxRaTQ9v

We would be delighted to hear from you at: [email protected]

About Bio Usawa, Inc.

Bio Usawa is Rwanda's pioneering biotechnology company dedicated to democratizing access to life-saving biotherapeutics across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies. For more information, visit www.biousawa.com.